Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

elated to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. 

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jason Rando (media)
                                        (646) 536-7025
                                        jrando@theruthgroup.com

                            NEUROGESX, INC.
           Condensed Consolidated Statements of Operations
            (in thousands, except share and per share data)
                             (unaudited)


                                      Three Months Ended   Nine Months Ended
                                         September 30,        September 30,
                                      ------------------   ------------------
                                       2009        2008      2009       2008
                                       ----        ----      ----       ----
    Collaboration revenue              $119        $--       $119        $--
                                      -----      -----     ------     ------
    Operating expenses:
    Research and development(1)       3,557      3,653      8,664     13,607
    General and administrative(2)     3,269      2,677      8,062      8,027
                                      -----      -----     ------     ------
    Total operating expenses          6,826      6,330     16,726     21,634
                                      -----      -----     ------     ------
    Loss from operations             (6,707)    (6,330)   (16,607)   (21,6
'/>"/>
SOURCE  NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... May 24, 2013 Many factors impact ... uptake or efflux transporters at the blood-tissue barrier. Even ... to unbound fractions in the tissue rather than the ... disposition challenges is required to guide lead optimization, predict ... any species-dependent variables that may impact the likely human ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... 19 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... II study with intramuscular (i.m.) injection of ... of seasonal and,life-threatening influenza. (Logo: ... a randomized, double-blind, placebo-controlled clinical,trial designed to ...
... 19 Health and Human,Services Secretary Mike ... the goal of personalized health care and ... and health care delivery should be,aligned to ... time" for each,individual patient., The report, ...
... Life,Sciences, Inc. (Nasdaq: CALP ) today announced that ... New York City will be webcast on,Tuesday, September 25 ... Caliper, will be providing an update on the company,s ... http://www.caliperls.com and clicking on the,link for the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7HHS Issues First Department-Wide Report on Personalized Health Care 2HHS Issues First Department-Wide Report on Personalized Health Care 3
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... release is available in Spanish . , Adolescents ... condition and regular physical activity present increased levels of insulin ... diabetes, appetite control and energy expenditure. This was the conclusion ... Physiology of the University of Granada . Further, after ...
... increasingly common and effective for operating inside the human ... tools inserted into the body of the patient, the ... determining the success of the operation. A team of ... a $2.3 million federal grant to develop a touch-sensitive ...
... next generation sequencing (NGS) and Certified Service Provider for ... a leading company in complex analysis and interpretation of ... complete human exome array, based on Roche NimbleGen sequence ... comprehensive service for human exome capture, targeted re-sequencing and ...
Cached Biology News:Children in good shape have better appetite control and energy expenditure 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 3Eurofins MWG Operon and Genomatix developed most complete human exome array 2
...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
Biology Products: